Literature DB >> 3005862

Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders.

D L Birx, R R Redfield, G Tosato.   

Abstract

Patients with the acquired immunodeficiency syndrome (AIDS) acquire undifferentiated B-cell lymphomas that are similar to African Burkitt's lymphoma and contain Epstein-Barr virus (EBV). Using an in vitro assay system that measures a complex of cellular responses to EBV-infected lymphocytes, we found that B cells from 7 patients with AIDS and from 10 patients with AIDS-related disorders produced abnormally low numbers of immunoglobulin-secreting cells (P less than 0.001 as compared with normal controls) and that T-cell suppression, which was greater than 80 percent in EBV-seropositive normal controls, was absent. Instead, the patients' T cells markedly increased immunoglobulin production induced by EBV. In further studies, we determined that the mean frequency of circulating EBV-infected B cells capable of spontaneous outgrowth in vitro was 13 per 10(6) B cells in 7 patients with AIDS and 21 per 10(6) B cells in 10 patients with AIDS-related disorders--figures that were significantly higher than the mean in normal controls (P less than 0.001). Thus, patients with AIDS or AIDS-related disorders may be predisposed to the development of EBV-containing lymphomas, because they have a profound defect of T-cell immunity to EBV and abnormally high numbers of EBV-infected B cells in the circulation.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3005862     DOI: 10.1056/NEJM198604033141403

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  64 in total

1.  Epstein-Barr and human immunodeficiency viruses in acquired immunodeficiency syndrome-related primary central nervous system lymphoma.

Authors:  S Morgello
Journal:  Am J Pathol       Date:  1992-08       Impact factor: 4.307

2.  Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity.

Authors:  M L Hammarskjöld; M C Simurda
Journal:  J Virol       Date:  1992-11       Impact factor: 5.103

3.  Activity of soluble factors produced by Epstein-Barr virus-transformed human B lymphocytes on different cell lines.

Authors:  C Garzelli; A Bazzichi
Journal:  Experientia       Date:  1991-07-15

4.  Subcellular distribution and life cycle of Epstein-Barr virus in keratinocytes of oral hairy leukoplakia.

Authors:  J P Rabanus; D Greenspan; V Petersen; U Leser; H Wolf; J S Greenspan
Journal:  Am J Pathol       Date:  1991-07       Impact factor: 4.307

5.  Intestinal manifestations of the acquired immunodeficiency syndrome.

Authors:  D P Kotler
Journal:  West J Med       Date:  1987-01

6.  The detection of Epstein-Barr virus in hairy cell leukemia cells by in situ hybridization.

Authors:  B C Wolf; A W Martin; R S Neiman; A J Janckila; L T Yam; A Caracansi; B A Leav; R Winpenny; D S Schultz; H J Wolfe
Journal:  Am J Pathol       Date:  1990-03       Impact factor: 4.307

Review 7.  Pathogenesis of AIDS-related lymphomas: molecular and histogenetic heterogeneity.

Authors:  G Gaidano; A Carbone; R Dalla-Favera
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

Review 8.  How I treat classical Hodgkin lymphoma in patients infected with human immunodeficiency virus.

Authors:  Thomas S Uldrick; Richard F Little
Journal:  Blood       Date:  2014-12-11       Impact factor: 22.113

9.  AIDS-related lymphoma. Histopathology, immunophenotype, and association with Epstein-Barr virus as demonstrated by in situ nucleic acid hybridization.

Authors:  S J Hamilton-Dutoit; G Pallesen; M B Franzmann; J Karkov; F Black; P Skinhøj; C Pedersen
Journal:  Am J Pathol       Date:  1991-01       Impact factor: 4.307

Review 10.  Neurologic presentations of AIDS.

Authors:  Elyse J Singer; Miguel Valdes-Sueiras; Deborah Commins; Andrew Levine
Journal:  Neurol Clin       Date:  2010-02       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.